SCHEMBL24254488

SCHEMBL24254488

Cc1ccc(S(=O)(=O)NCc2ccccc2)cc1NC(=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.58
MEN1 O00255 4/20 0.58
PRMT1 Q99873 1/20 0.58
KDM4E B2RXH2 1/20 0.57
ALDH1A1 P00352 1/20 0.57
LMNA P02545 4/20 0.54
SLC12A2 P55011 1/20 0.54
SLC12A5 Q9H2X9 1/20 0.54
GAA P10253 1/20 0.52
HPGD P15428 1/20 0.52
MAPT P10636 4/20 0.52
TP53 P04637 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
GRIN1 Q05586 1/20 0.51
GRIN2A Q12879 1/20 0.51
GRIN2B Q13224 1/20 0.51
HTT P42858 2/20 0.50
GLA P06280 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC8 Q9BY41 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24254499 0.84 LMNA (0.53) KMT2AMEN1ALDH1A1LMNASLC12A2
SCHEMBL8914972 0.74 LMNA (0.69) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL19400889 0.73 NPC1 (0.73) KMT2AALDH1A1LMNASLC12A2SLC12A5
SCHEMBL13186798 0.72 KMT2A (0.85) KMT2AMEN1ALDH1A1LMNASLC12A2
SCHEMBL31689615 0.72 CA12 (0.63) KMT2AALDH1A1LMNASLC12A2SLC12A5
SCHEMBL24254494 0.72 EPHX2 (0.55) ALDH1A1LMNAHPGDMAPTSMN1; SMN2
SCHEMBL24254503 0.71 MGAT2 (0.54) KMT2AMEN1ALDH1A1LMNAMAPT
SCHEMBL12077462 0.70 NAMPT (0.79) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL12078707 0.70 NAMPT (0.75) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL27920895 0.70 EPHX2 (0.80) KMT2AMEN1ALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP1 KMT2A 326/4885MEN1 3058/4885PRMT1 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.